FINWIRES · TerminalLIVE
FINWIRES

HKG:1466

3 stories mentioning HKG:1466Updated 40d ago

Every FINWIRES story that references HKG:1466, newest first.

Asia

Baijin Life Science Flags Up to HK$43 Million Full-Year Loss

Baijin Life Science (HKG:1466) said it expects to record up to HK$43 million in loss for the fiscal year ended March 31, widening from a loss of HK$100,000 a year earlier, according to a Monday filing with the Hong Kong bourse.The firm attributed the higher loss to a drop in revenue and gross profit, mainly from its jewellery business.The company also saw a rise in the cost of sales from its skincare business.The company's financial results are due June 30.

HKG:1466
Asia

Baijin Life Science Unit, Foryoung Tie Up for Clinical Cell Therapy Business

Baijin Life Science (HKG:1466) unit Beijing Baijin Biotechnology entered into an agreement with Foryoung Biotechnology for strategic cooperation, according to a Wednesday filing with the Hong Kong bourse.The parties will cooperate in the clinical cell therapy niche.Beijing Baijin Biotechnology will be responsible for the R&D, production, quality control, and global supply chain support of various products, with Foryoung Biotechnology integrating its technological capabilities in the process.

HKG:1466
Asia

Baijin Life Science Grants 67.9 Million Share Options

Baijin Life Science (HKG:1466) granted over 67.9 million share options to various directors and employees under a 2024 incentive scheme, according to a Friday Hong Kong bourse filing.The options are exercisable into an equal number of ordinary shares in the firm's share capital for five years at HK$0.54 apiece.The options are not subject to performance targets.The jewelry maker now has no shares available for future grant under the scheme.

HKG:1466

Track with the FINWIRES app suite

FolioX
FolioX
Track HKG:1466 in your portfolio
WheelAI
WheelAI
Analyze HKG:1466 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on HKG:1466